- Home
- HOPE vs IMCR Comparison
HOPE vs IMCR Comparison
Compare HOPE & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOPE
- IMCR
- Stock Information
- Founded
- HOPE 1986
- IMCR 2008
- Country
- HOPE United States
- IMCR United Kingdom
- Employees
- HOPE N/A
- IMCR N/A
- Industry
- HOPE Major Banks
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HOPE Finance
- IMCR Health Care
- Exchange
- HOPE Nasdaq
- IMCR Nasdaq
- Market Cap
- HOPE 1.3B
- IMCR 1.5B
- IPO Year
- HOPE 1996
- IMCR 2021
- Fundamental
- Price
- HOPE $11.16
- IMCR $32.77
- Analyst Decision
- HOPE Buy
- IMCR Buy
- Analyst Count
- HOPE 3
- IMCR 10
- Target Price
- HOPE $13.50
- IMCR $58.13
- AVG Volume (30 Days)
- HOPE 829.5K
- IMCR 445.1K
- Earning Date
- HOPE 07-28-2025
- IMCR 08-07-2025
- Dividend Yield
- HOPE 5.22%
- IMCR N/A
- EPS Growth
- HOPE N/A
- IMCR N/A
- EPS
- HOPE 0.78
- IMCR N/A
- Revenue
- HOPE $448,793,000.00
- IMCR $333,581,000.00
- Revenue This Year
- HOPE $17.54
- IMCR $26.82
- Revenue Next Year
- HOPE $12.05
- IMCR $8.15
- P/E Ratio
- HOPE $13.76
- IMCR N/A
- Revenue Growth
- HOPE N/A
- IMCR 25.75
- 52 Week Low
- HOPE $8.83
- IMCR $23.15
- 52 Week High
- HOPE $14.54
- IMCR $41.54
- Technical
- Relative Strength Index (RSI)
- HOPE 60.68
- IMCR 45.73
- Support Level
- HOPE $10.10
- IMCR $30.76
- Resistance Level
- HOPE $10.95
- IMCR $32.55
- Average True Range (ATR)
- HOPE 0.22
- IMCR 1.39
- MACD
- HOPE 0.06
- IMCR -0.41
- Stochastic Oscillator
- HOPE 79.38
- IMCR 19.09
About HOPE Hope Bancorp Inc.
Hope Bancorp Inc is a bank holding company engaged in providing financial services. It offers core business banking products for small and medium-sized businesses and individuals. Services offered by the bank include online banking, mobile banking, mortgage loans, credit cards, investment and wealth management services and other banking services.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.